Nuclidium raises over CHF100 million ($121M) to develop copper-based radiopharmaceuticals for cancer diagnosis and treatment.
Amount Raised
$121 Million
Round Type
Venture
BaselBiotechnologyHealth CareTherapeuticsInvestors
Description
Nuclidium, a Basel-based biotech startup founded in 2021, has raised over CHF100 million ($121 million) to advance its copper-based radiopharmaceuticals pipeline for diagnosing and treating cancers including metastatic prostate and breast cancer. The company's theranostic approach uses matched pairs of copper isotopes to both detect and treat cancer targets. CEO Leila Jaafar emphasizes that demonstrating clinical efficacy remains the primary challenge ahead. The US market for metastatic prostate cancer diagnosis and treatment alone is estimated to exceed $50 billion annually.
Quick answer
Nuclidium raised $121 Million in a funding round, dated September 26, 2026. Investors: Wellington Partners and Angelini Ventures. Nuclidium is based in Basel, Basel City, Switzerland.
- How much did Nuclidium raise?
- Nuclidium raised $121 Million in a funding round on September 26, 2026.
- Who invested in Nuclidium?
- Wellington Partners and Angelini Ventures are named as investors in this round.
- What does Nuclidium do?
- Nuclidium is a clinical-stage biotechnology company based in Basel, Switzerland, developing innovative copper-based radiopharmaceuticals for the diagnosis and treatment of cancer.
- Where is Nuclidium based and how big is it?
- Nuclidium is based in Basel, Basel City, Switzerland. Fundz records about 27 employees.
- Who are the decision-makers at Nuclidium?
- Fundz holds 2 contacts at Nuclidium, including the Head of Clinical Operations. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Who else raised in Therapeutics and Biotechnology around the same time
Companies in the same sectors as Nuclidium that raised within 45 days of this round, from Fundz verified event records.
- Oyster Therapeutics raised $60M (Series A) on November 10, 2026.
- SRTD biotech raised $35M (Seed) on November 9, 2026.
- BioVie raised $4.7M (Post-IPO Equity) on November 6, 2026.
- Alethio raised $90M (Series A) on November 5, 2026.
- Biograil raised $22M on November 4, 2026.
- MyoPax raised an undisclosed amount (Pre-Seed) on November 4, 2026.
Who to call at Nuclidium, and when
A new round usually means Nuclidium is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day Nuclidium raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Nuclidium, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Nuclidium. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Nuclidium raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Nuclidium raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.